JP2016518403A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518403A5
JP2016518403A5 JP2016512480A JP2016512480A JP2016518403A5 JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5 JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016512480 A JP2016512480 A JP 2016512480A JP 2016518403 A5 JP2016518403 A5 JP 2016518403A5
Authority
JP
Japan
Prior art keywords
trehalose
pharmaceutical
pharmaceutical formulation
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016512480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518403A (ja
JP6837835B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050411 external-priority patent/WO2014181333A2/en
Publication of JP2016518403A publication Critical patent/JP2016518403A/ja
Publication of JP2016518403A5 publication Critical patent/JP2016518403A5/ja
Application granted granted Critical
Publication of JP6837835B2 publication Critical patent/JP6837835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016512480A 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 Active JP6837835B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361820278P 2013-05-07 2013-05-07
US61/820,278 2013-05-07
PCT/IL2014/050411 WO2014181333A2 (en) 2013-05-07 2014-05-07 Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019075517A Division JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Publications (3)

Publication Number Publication Date
JP2016518403A JP2016518403A (ja) 2016-06-23
JP2016518403A5 true JP2016518403A5 (enExample) 2017-06-15
JP6837835B2 JP6837835B2 (ja) 2021-03-03

Family

ID=51022384

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016512480A Active JP6837835B2 (ja) 2013-05-07 2014-05-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019075517A Pending JP2019142907A (ja) 2013-05-07 2019-04-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2021095562A Pending JP2021152032A (ja) 2013-05-07 2021-06-08 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2023002536A Pending JP2023040211A (ja) 2013-05-07 2023-01-11 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
JP2025036306A Pending JP2025087858A (ja) 2013-05-07 2025-03-07 トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療

Country Status (14)

Country Link
US (4) US10493023B2 (enExample)
EP (2) EP4218769A3 (enExample)
JP (5) JP6837835B2 (enExample)
KR (1) KR20160009617A (enExample)
AU (5) AU2014264228A1 (enExample)
CA (2) CA3239805A1 (enExample)
CR (1) CR20150637A (enExample)
EA (1) EA201501054A1 (enExample)
IL (1) IL241757B (enExample)
MD (1) MD20150120A2 (enExample)
MX (1) MX2015015355A (enExample)
PE (1) PE20160012A1 (enExample)
SG (1) SG11201509030TA (enExample)
WO (1) WO2014181333A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084720B2 (en) * 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
US20220288096A1 (en) * 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
CA3239805A1 (en) 2013-05-07 2014-11-13 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US10736909B2 (en) * 2016-02-08 2020-08-11 Junaxo, Inc. Use of trehalose for treatment of neurological diseases
NZ748599A (en) 2016-04-21 2022-08-26 Baylor College Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
LT4154882T (lt) 2017-08-14 2025-11-25 Amiotrofinės lateralinės sklerozės gydymas pridopidinu
WO2019143685A1 (en) 2018-01-16 2019-07-25 Women & Infants Hospital Of Rhode Island Methods and compositions for treating pre-eclampsia
BR112022006012A2 (pt) * 2019-10-01 2022-07-12 Seelos Therapeutics Inc Formulações de trealose e usos das mesmas
AU2021219072B2 (en) * 2020-02-13 2024-10-03 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2022013940A1 (ja) 2020-07-14 2022-01-20 オリンパス株式会社 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体
CN116966192A (zh) * 2022-09-26 2023-10-31 西安文理学院 海藻糖在制备sca3疾病治疗药物中的应用
AU2023403437A1 (en) * 2022-11-30 2025-06-19 GLD Debt Acquisition 2025-1, Inc. Trehalose for treating huntington's disease

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3782404A (en) 1972-06-14 1974-01-01 Commercial Shearing Adjustable, metered, directional flow control arrangements
JPS4950521U (enExample) 1972-08-14 1974-05-02
JPS516109B2 (enExample) 1972-12-28 1976-02-25
JPS557829Y2 (enExample) 1974-07-01 1980-02-21
JPS516109A (en) 1974-07-05 1976-01-19 Toshiba Tungaloy Co Ltd Aruminaatankachitan chitsukachitankeishoketsugokin
AU1172097A (en) 1995-12-27 1997-07-28 Rohto Pharmaceutical Co., Ltd. Pharmaceutical composition containing trehalose
JP4033510B2 (ja) 1995-12-27 2008-01-16 ロート製薬株式会社 トレハロースを含有する眼科用医薬組成物
JP3455633B2 (ja) 1996-06-28 2003-10-14 味の素ファルマ株式会社 潰瘍性大腸炎の予防又は治療剤
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6602865B1 (en) 1998-11-16 2003-08-05 Ivax Drug Research Institute, Ltd. Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP2001302517A (ja) * 2000-04-24 2001-10-31 Tokyo Univ Of Pharmacy & Life Science 脳浮腫の予防治療薬
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
EP3143983A1 (en) 2003-02-13 2017-03-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo External dermatological formulation comprising saccharide derivative of alpha, alpha-trehalose
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2006124892A2 (en) 2005-05-13 2006-11-23 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
MY142987A (en) 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
JP2006342108A (ja) * 2005-06-09 2006-12-21 Mitsubishi Chemicals Corp アミロスフェロイドにより発生する疾患の予防治療剤
WO2007018124A1 (ja) 2005-08-11 2007-02-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo コラーゲン産生増強剤とその用途
KR101413770B1 (ko) 2005-11-30 2014-06-30 닛신 오일리오그룹 가부시키가이샤 트레할로오스 지방산 에스테르 조성물
JP4950521B2 (ja) 2006-03-08 2012-06-13 公益財団法人野口研究所 トレハロース誘導体とその製造法
EP2000473B1 (en) 2006-03-27 2011-04-06 Otsuka Chemical Co., Ltd. Trehalose compound and pharmaceutical comprising the compound
CN100571707C (zh) 2006-07-24 2009-12-23 凌沛学 含有海藻糖的关节腔内注射给药制剂
US20100093993A1 (en) 2007-01-31 2010-04-15 Otsuka Chemical Co., Ltd. Trehalose compound, process for production of the compound, and immuno-stimulative agent comprising the compound
CN101646442B (zh) * 2007-02-23 2013-09-04 21世纪国际新技术株式会社 血管痉挛的治疗剂或预防剂
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2009058399A1 (en) * 2007-10-31 2009-05-07 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
JP2009249292A (ja) * 2008-04-01 2009-10-29 Toray Ind Inc ポリリン酸を安定化剤とするエリスロポエチン溶液製剤
US20110142799A1 (en) * 2008-06-23 2011-06-16 President And Fellows Of Harvard College Modulation of neurodegenerative disease by modulating xbp-1 activity
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
EP2351764A4 (en) 2008-10-31 2012-09-05 Otsuka Chemical Co Ltd TREHALOSE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND
CN102438652B (zh) * 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
MX367131B (es) 2008-12-10 2019-08-06 Wista Lab Ltd Sales de xantilio 3,6-disustituidas.
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
JP5869882B2 (ja) * 2010-03-05 2016-02-24 株式会社林原 インスリン抵抗性の予防及び／又は改善剤
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
CN101914118B (zh) 2010-08-06 2012-07-04 山东大学 海藻糖衍生物及其制备方法与应用
WO2012061907A2 (en) * 2010-11-10 2012-05-18 Katholieke Universiteit Leuven Osteoclast activity
US9186356B2 (en) 2011-01-08 2015-11-17 Academia Sinica Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U)
CN103764824B (zh) 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
US8623839B2 (en) * 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130310467A1 (en) 2012-03-06 2013-11-21 The Nisshin Oillio Group, Ltd. Trehalose fatty acid ester composition
JP5432322B2 (ja) 2012-05-08 2014-03-05 株式会社大塚製薬工場 トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液
US20130312784A1 (en) 2012-05-24 2013-11-28 For Your Ease Only, Inc. Cosmetic organizer
US20140032304A1 (en) 2012-07-27 2014-01-30 Google Inc. Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal
JP2014139160A (ja) 2012-12-21 2014-07-31 Masaaki Hayashibara 脳機能改善剤及び脳機能改善用食品
CA3239805A1 (en) 2013-05-07 2014-11-13 Seelos Therapeutics, Inc. Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US20220288096A1 (en) 2013-05-07 2022-09-15 Seelos Therapeutics, Inc. Compositions and methods for treating an aggregation disease or disorder
US9084720B2 (en) 2013-05-07 2015-07-21 BioBlast Pharma Ltd. Compositions and methods for treating oculopharyngeal muscular dystrophy
JP6130224B2 (ja) 2013-05-27 2017-05-17 公益財団法人微生物化学研究会 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物
TWI507197B (zh) 2013-07-17 2015-11-11 Univ Nat Taiwan Normal 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途
US10906981B2 (en) 2013-07-19 2021-02-02 The Regents Of The University Of California Compositions and methods related to structures that cross the blood brain barrier
US20170354666A1 (en) 2014-11-19 2017-12-14 Rush University Medical Center Compositions and methods for treating lysosomal disorders
US20160303150A1 (en) 2015-04-16 2016-10-20 BioBlast Pharma Ltd. Deuterated trehalose formulations and uses thereof
WO2017136533A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses
NZ748599A (en) 2016-04-21 2022-08-26 Baylor College Medicine Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction
BR112022006012A2 (pt) 2019-10-01 2022-07-12 Seelos Therapeutics Inc Formulações de trealose e usos das mesmas

Similar Documents

Publication Publication Date Title
JP2016518403A5 (enExample)
US12343342B2 (en) Methods for treating soft tissue sarcoma
US20220112277A1 (en) Anti-CGRP Antibody Formulation
KR101907411B1 (ko) 코엔자임 Ｑ10(ＣｏＱ10)의 정맥내 제형 및 이의 사용 방법
Malär et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
EP2938325B1 (en) Diclofenac composition
CN101677987A (zh) 不含吐温80的多西他赛的增溶制剂
CN113797343A (zh) 使用辅酶q10联合疗法治疗癌症
KR20180008305A (ko) 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물
EP3285758B1 (en) Co-crystal composition and its pharmaceutical use
JP2016516773A5 (enExample)
EP3528786B1 (en) Liquid formulations of daptomycin
CN110035740A (zh) 稳定的水性辣椒素可注射制剂及其医学用途
JP2019530648A5 (enExample)
CN107810000A (zh) 来氟米林的可注射药物组合物
EP3881856A1 (en) Pharmaceutical composition for treating aplastic anemia
EP2974723A1 (en) Application of phthalide compound
US20220211663A1 (en) Nano co-delivery of quercetin and alantolactone promotes anti-tumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer
CN102481342A (zh) 使用促皮质素释放因子治疗癌症的方法
JP2016537428A (ja) エフェドラ・アラタ抽出物及びその使用方法
EP4076417A1 (en) Caffeine citrate formulations
CN100444836C (zh) 含有丹参素钠的注射组合物
JP2020172471A (ja) ヒト化抗ヒトｃｄ２６抗体を含有する医薬組成物
EP3632446B3 (en) Immunoablative therapies
Kumar et al. Parenteral Suspensions: Stability Enhancing Liquid Dosage Forms